GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) inhibitor.

Genz-882706 enhances proliferative activity in unstimulated cells 48 hours post-treatment.

Daily administration of Genz-882706 markedly attenuates experimental autoimmune encephalomyelitis (EAE) severity. In EAE-affected mice, Genz-882706 significantly lowers MCP-1, IL-6, IL-1β, and IP-10 levels in spinal cord homogenates, contrasting sharply with those treated with a vehicle. Conversely, TNF-α levels in the spinal cord notably increase following Genz-882706 treatment compared to the vehicle group. Furthermore, Genz-882706 administrations, at both 30 mg/kg and 100 mg/kg dosages, substantially decrease the population of microglia and monocytes/macrophages in the brain and spinal cord, standing out from vehicle and LPS controls. Additionally, Genz-882706 modestly diminishes CD80 expression on monocytes/macrophages within the brain.